Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma

Pathology Research and Practice

Volumn 200, Issue 6, 2004, Pages 439-445

  Park, Hye Rim ^a   Won Jung, Woon ^b   Bertoni, Franco ^c   Bacchini, Patrizia ^c   Hoon Park, Jae ^d   Kim, Youn Wha ^d   Park, Yong Koo ^d  

^a Hallym University   (South Korea)

^b MyGene Company   (South Korea)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d Kyung Hee University   (South Korea)

Author keywords

H ras; Low grade osteosarcoma; MDM2; P53

Indexed keywords

FORMALDEHYDE; MONOCLONAL ANTIBODY KI 67; PARAFFIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RAS PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GENE ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MUTATION; ONCOGENE H RAS; OSTEOSARCOMA; PRECANCER; TISSUE FIXATION;

EID: 3142697631     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prp.2004.04.006     Document Type: Article

References (35)

1. Antillon-Kussmann F. Garcia-Delgado M. Villa-Elizaga I. Sierrasesumaga L. Mutational activation of ras genes is absent in pediatric osteosarcoma Cancer Genet. Cytogenet. 79 1995 49-53
2. Bellido T. O'Brien C.A. Roberson P.K. Manolagas S.C. Transcriptional activation of the p21WAF1,CIP1,SAI1 gene by interleukin-6 type cytokines J. Biol. Chem. 273 1998 21137-21144
3. Bohle R.M. Brettreich S. Repp R. Borkhardt A. Kosmehl H. Altmannsberger H.M. Single somatic ras gene point mutation in soft tissue malignant fibrous histiocytomas Am. J. Pathol. 148 1996 731-738
4. Choong P.F. Pritchard D.J. Rock M.G. Sim F.H. McLeod R.A. Unni K.K. Low grade central osteogenic sarcoma. A long-term follow-up of 20 patients Clin. Orthop. 322 1996 198-206
5. Cordon-Cardo C. Latres E. Drobnjak M. Oliva M.R. Pollack D. Woodruff J.M. Marechal V. Chen J. Brennan M.F. Levine A.J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas Cancer. Res. 54 1994 794-799
6. Dobashi Y. Sugimura H. Sato A. Hirabayashi T. Kanda H. Kitagawa T. Kawaguchi N. Imamura T. Machinami R. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma Diagn. Mol. Pathol. 2 1993 257-263
7. El-Deiry W.S. Tokino T. Velculescu V.E. Levy D.B. Parsons R. Trent J.M. Lin D. Mercer W.E. Kinzler K.W. Vogelstein B. WAF1, a potential mediator of p53 tumor suppression Cell. 75 1993 817-825
8. Franchi A. Calzolari A. Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton Virchows Arch. 432 1998 515-519
9. Gerdes J. Lemke H. Naisch H. Wacker H.H. Schwab U. Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 J. Immunol. 133 1984 1710-1715
10. Gisselsson D. Palsson E. Hoglund M. Domanski H. Mertens F. Pandis N. Sciot R. Cin P.D. Bridge J.A. Mandahl N. Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma Genes Chromosomes Cancer 33 2002 133-140
11. Gokgoz N. Wunder J.S. Mousses S. Eskandarian S. Bell R.S. Andrulis I.L. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma Cancer 92 2001 2181-2189
12. Hunter T. Braking the cycle Cell 75 1993 839-841
13. Kawaguchi K.I. Oda Y. Sakamoto A. Saito T. Tamiya S. Iwamoto Y. Tsuneyoshi M. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years Mod. Pathol. 15 2002 878-888
14. Kreicbergs A. Silvfersward C. Tribukait B. Flow DNA analysis of primary bone tumors. Relationship between cellular DNA contents and histopathologic classification Cancer 53 1984 129-136
15. Lonardo F. Ueda T. Huvos A.G. Healey J. Ladanyi M. P53 and MDM2 alterations in osteosarcomas. Correlation with clinicopathologic features and proliferative rate Cancer 79 1997 1541-1547
16. McClelland R.A. Gee J.M. O'Sullivan L. Barnes D.M. Robertson J.F.R. Ellis I.O. Nicholson R.I. P21 WAF1 expression and endocrine response in breast cancer J. Pathol. 188 1999 126-132
17. Miller C.W. Aslo A. Won A. Tan M. Lampkin B. Koeffler P. Alterations of the p53, Rb and MDM2 gene in osteosarcomas J. Cancer Res. Clin. Oncol. 122 1996 559-565
18. Nakayama T. Toguchida J. Wadayama B. Kanoe H. Kotoura Y. Sasaki M.S. MDM2 gene amplification in bone and soft tissue tumors: association with tumor progression in differentiated adipose tissue tumors Int. J. Cancer 64 1995 342-346
19. Oda Y. Wehrmann G. Radig K. Walter H. Rose I. Neumann W. Roessner A. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression Gen. Diagn. Pathol. 141 1995 97-103
20. Oliner J.D. Kinzler K.W. Meltzer P.S. George D.L. Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas Nature 358 1992 80-83
21. Oliner J.D. Pietenpol J.A. Thiagalingam S. Gyuris J. Kinzler K.W. Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53 Nature 362 1993 857-860
22. Park H.R. Park Y.K. Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone J. Korean Med. Sci. 10 1995 360-367
23. Paulovich A.G. Toxyzski D.P. Hartwell L.H. When checkpoint fail Cell 88 1997 315-321
24. Pompetti F. Rizzo P. Simon R.M. Freidlin B. Mew D.J. Pass H.I. Picci P. Levine A.S. Carbone M. Oncogene alterations in primary, recurrent, and metastastic human bone tumors J. Cell Biochem. 63 1996 37-50
25. Radig K. Schneider-Stock R. Haeckel C. Neumann W. Roessner A. P53 gene mutations in osteosarcomas of low-grade malignancy Hum. Pathol. 29 1998 1310-1316
26. Ragazzini P. Gamberi G. Benassi M.S. Orlando C. Sestini R. Ferrari C. Molendini L. Sollazzo M.R. Merli M. Magagnoli G. Bertoni F. Bohling T. Pazzagli M. Picci P. Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma Cancer Detect. Prev. 23 1999 129-136
27. Reid A.H. Tsai M.M. Venzon D.J. Wright C.F. Lack E.E. O'Leary T.J. MDM2 amplification, p53 mutation, and accumulation of the p53 gene product in malignant fibrous histiocytoma Diagn. Mol. Pathol. 5 1996 65-73
28. Szymanska J. Mandahl N. Mertens F. Tarkkanen M. Karaharju E. Knuutila S. Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13 to 15: a combined cytogenetic and comparative genomic hybridization study Genes Chromosome Cancer 16 1996 31-34
29. Tarkkanen M. Bohling T. Gamberi G. Ragazzini P. Benassi M.S. Kivioja A. Kallio P. Elomaa I. Picci P. Knuutila S. Comparative genomic hybridization of low-grade central osteosarcoma Mod. Pathol. 11 1998 421-426
30. Tsuchiya T. Sekine K. Hinohara S. Namiki T. Nobori T. Kaneko Y. Analysis of the p16INK4, p41ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma Cancer Genet. Cytogenet. 120 2000 91-98
31. Unni K.K. Dahlin D.C. Grading of bone tumors Semin. Diagn. Pathol. 1 1984 165-172
32. Wunder J.S. Czitrom A.A. Kandel R. Andrulis I.L. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas J. Natl. Cancer Inst. 83 1991 194-200
33. Xiao Z.X. Chen J. Levine A. Modjtahedi N. Xing J. Sellers W.R. Livingston D.M. Interaction between the retinoblastoma protein and the oncoprotein MDM2 Nature 375 1995 694-698
34. Yokoyama R. Schneider-Stock R. Radig K. Wex T. Roessner A. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors Pathol. Res. Pract. 194 1998 615-621
35. Zenmyo M. Komiya S. Hamada T. Hiraoka K. Kato S. Fujii T. Yano H. Irie K. Nagata K. Transcriptional activation of p21 by Vitamin D3 or Vitamin K2 leads to differentiation of p53-deficient MG-63 osteosarcoma cells Hum. Pathol. 32 2001 410-416